Results 101 to 110 of about 70,369 (254)

A new perspective on radiotherapy in the comprehensive treatment of cancer

Precision Radiation Oncology, EarlyView.
Radiotherapy remains a key component in the comprehensive management of cancer. Its effectiveness is significantly improved through strategic combinations with chemotherapy, targeted therapy, and immunotherapy, providing a range of therapeutic outcomes from cure to palliative care.
Yingze Ma, Hongxuan Yu, Shijie Shang, Shixin Shan, Dawei Chen   +4 more
wiley   +1 more source

DNA methylation remodeling in temozolomide resistant recurrent glioblastoma: comparing epigenetic dynamics in vitro and in vivo

Journal of Translational Medicine
Background Glioblastoma is the most aggressive type of brain tumor and is associated with a poor prognosis. First-line treatment is surgical resection followed by radiotherapy and temozolomide-based chemotherapy.
Michela Buonaiuto, Mariella Cuomo, Davide Costabile, Federica Trio, Sara Ferraro, Ornella Affinito, Alberto De Bellis, Maria Laura Del Basso De Caro, Roberta Visconti, Lorenzo Chiariotti, Giuseppe Catapano, Rosa Della Monica   +11 more
doaj   +1 more source

A Rapid Biochemical and Radiological Response to the Concomitant Therapy with Temozolomide and Radiotherapy in an Aggressive ACTH Pituitary Adenoma

Case Reports in Endocrinology, 2017
Background and Importance. In the last eight years temozolomide (TMZ) has been used as the last-line treatment modality for aggressive pituitary tumors to be applied after the failure of surgery, medical therapy, and radiotherapy.
Ana Misir Krpan, Tina Dusek, Zoran Rakusic, Mirsala Solak, Ivana Kraljevic, Vesna Bisof, David Ozretic, Darko Kastelan   +7 more
doaj   +1 more source

Patient‐derived surgical samples reveal the cellular and molecular signatures of glioblastoma infiltration in distinct radiological zones

Brain Pathology, EarlyView.
Integrated histological and transcriptional profiling of the glioblastoma periphery reveals clinically relevant tumor infiltration beyond MRI‐defined boundaries. MRI‐guided biopsies from contrast‐enhancing (CE), non‐contrast‐enhancing (nCE), edema (E), and radiologically normal (N) regions demonstrate that nCE areas frequently retain neoplastic and ...
Olaya de Dios, Juan Romero, María de los Ángeles Ramírez‐González, Beatriz Herranz, Alicia Avis‐Bodas, Juliana Manosalva, Diego Megías, Ana Ramos, Juan Manuel Sepúlveda‐Sánchez, Ricardo Gargini, Berta Segura‐Collar, Gabriel Velilla, Bárbara Meléndez, Pedro González, Luis Jiménez‐Roldán, Guillermo García‐Posadas, Aurelio Hernández‐Laín, Ángel Pérez‐Núñez, Pilar Sánchez‐Gómez   +18 more
wiley   +1 more source

MAP17 Enhances Chemoresistance and Tumorigenicity of Glioblastoma‐Initiating Cells via the Canonical NF‐кB Pathway

Cancer Science, EarlyView.
MAP 17 is identified as highly expressed in TMZ‐resistant glioblastoma‐initiating cells (GICs). MAP17 enhances GIC proliferation, TMZ resistance, and tumorigenicity through NF‐κB/RELA‐dependent BCL2 upregulation. ABSTRACT Glioblastoma (GBM) is the most common malignant brain tumor in adults.
Shenshen Dou, You Lee Son, Toru Kondo
wiley   +1 more source

Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide

, 2002
PURPOSE: Temozolomide is a novel oral alkylating agent with demonstrated efficacy as second-line therapy for patients with recurrent anaplastic astrocytoma and glioblastoma multiforme (GBM).
Reto Meuli, Sandrine Ostermann Kraljevic, René O. Mirimanoff, Roger Stupp, François Porchet, Luca Regli, Gianpaolo Pizzolato, Ivan Maillard, Robert Janzer, Alessia Pica, Phillipe Maeder, Serge Leyvraz, Pierre-Yves Dietrich, Raymond Miralbell, Nicolas de Tribolet   +14 more
core   +1 more source

Circadian rhythms in pediatric high-grade gliomas may contribute to treatment efficacy

Scientific Reports
Pediatric high-grade gliomas (pHGG) are highly invasive with poor survival outcomes. Timing of Temozolomide administration has been shown to affect survival of adult patients with glioblastoma.
Ella A. Nettnin, Cesar A. Garcia, Fudhial F. Sayed, Ethan Schonfeld, Thien Nguyen, Maria Isabel Barros Guinle, Claudia K. Petritsch, Erin M. Gibson, Laura M. Prolo   +8 more
doaj   +1 more source

hsa-miR-34a-5p enhances temozolomide anti-tumoral effects on glioblastoma

EXCLI Journal : Experimental and Clinical Sciences
Glioblastoma multiform (GBM) is a commonly diagnosed brain neoplasm with a poor prognosis. Accumulating evidence has highlighted the significance of microRNA (miR) dysregulation in tumor development and progression.
Mahdi Abdoli Shadbad, Amir Baghbanzadeh, Behzad Baradaran   +2 more
doaj   +1 more source

Elucidating the Pro‐Tumor Role of LncRNA CROCCP2 in Glioma via the miR‐5584‐5p/HOXD11/Autophagy Pathway

Cancer Science, EarlyView.
The lncRNA CROCCP2 upregulates HOXD11 by competitively adsorbing miR‐5584‐5p, thereby promoting glioma cell proliferation, migration, and invasion by inhibiting autophagy. It significantly enhances tumor growth in vivo, suggesting it may be a potential therapeutic target for gliomas.
Feng Wang, Ganni Lei, Yuan Peng, Maoqiao Liu, Tianqi Jiang, Minghui Wang, Zhe Wang, Jun Pu, Jia Liu   +8 more
wiley   +1 more source

Efficacy of temozolomide in children with solid tumors

, 2020
Temozolomide, an alkylating drug first adopted to treat patients with malignant gliomas, is actually an antineoplastic drug used in various regimens against childhood tumors. Treatment with temozolomide is an effective therapy for different childhood
Ruggiero A., Mastrangelo S., Maurizi P.
core   +1 more source